Microsatellite instability and mutation analysis of candidate genes in unselected Sardinian patients with endometrial carcinoma

BACKGROUND. Microsatellite instability (MST) is due mostly to a defective DNA mismatch repair (MMR). Inactivation of the two principal MMR genes, hMLH1 and hMSH2, and the PTEN tumor suppressor gene seems to be involved in endometrial tumorigenesis. In this study, Sardinian patients with endometrial carcinoma (EC) were analyzed to assess the prevalence of both the mutator phenotype (as defined by the presence of MST and abnormal MMR gene expression at the somatic level) and the hMLH1, hMSH2, and PTEN germline mutations among patients with MST positive EC. METHODS. Paraffin embedded tissue samples from 116 consecutive patients with EC were screened for MST by polymerase chain reaction-based microsatellite analysis. Immunohistochemistry (IHC) with anti-hMLH1 and anti-hMSH2 antibodies was performed on MST positive tumor tissue sections. Germline DNA was used for mutational screening by denaturing high-performance liquid chromatography analysis and automated sequencing. RESULTS. Thirty-nine patients with EC (34%) exhibited MST; among them, 25 tumor samples (64%) showed negative immunostaining for hMLH1/hMSH2 proteins (referred to as IHC negative). No disease-causing mutation within the coding sequences of the hMLH1/hMSH2 and PTEN genes was found in patients with EC who had the mutator phenotype (MST positive and IHC negative), except for a newly described hMLH1 missense mutation, Ile655VaI, that was observed in 1 of 27 patients (4%). Although MST was more common among patients with advanced-stage EC and increased as the tumor grade increased, no significant correlation with disease free survival or overall survival was observed among the two groups (MST positive or MST negative) of patients with EC. CONCLUSIONS. in patients with MST positive EC, epigenetic inactivations rather than genetic mutations of the MMR genes seem to be involved in endometrial tumorigenesis. No prognostic value was demonstrated for MST in patients with EC. (C) 2002 American Cancer Society.